Peter Grayson, M.D., M.Sc.

Dr. Grayson's research focuses on clinical and translational research across many forms of systemic vasculitis. Specifically, his work has focused on biomarker discovery/development, advanced molecular imaging, molecular classification of disease, clinical trials, and genetics/genomics of vasculitis. His group co-discovered the VEXAS syndrome in 2020. His group has clinically defined advanced molecular imaging as a surrogate marker of vascular inflammation in large-vessel vasculitis.

His group has conducted some of the only translational work related to relapsing polychondritis, including identifying somatic mutations in UBA1 as a driver of disease in a subset of these patients. Translational work from the group has also defined novel pathways of neutrophil-mediated inflammation in monogenic vasculitis and drug-induced vasculitis and has identified novel biomarkers of disease activity in many forms of vasculitis that suggest novel therapeutic targets.

Peter Grayson, M.D., M.Sc., is a senior investigator at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). He completed his undergraduate degree from Brown University in 1999, his medical degree from the Medical University of South Carolina in 2004, and his master's in science from Boston University in 2008. He served as a chief resident in Internal Medicine at Boston Medical Center and completed an additional two-year vasculitis fellowship within the Vasculitis Clinical Research Consortium.

Dr. Grayson is firmly committed to mentoring young investigators in rare disease research. He served as the acting program director for the NIAMS Rheumatology Fellowship Program and is the recipient of numerous teaching awards. He received the American College of Rheumatology's Distinguished Fellow Award in 2011 and was elected into the American Society for Clinical Investigation in 2024.